Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA
NCT ID: NCT03404479
Last Updated: 2018-02-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
90 participants
INTERVENTIONAL
2018-01-25
2019-01-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
NCT02688400
Effectiveness and Safety of Celecoxib (Celebrex 200 mg) Combined With Joins in the Treatment of Degenerative Knee Osteoarthritis: a Randomized Controlled Trial
NCT04718649
Symptomatic Efficacy of Diacerein in Knee Osteoarthritis
NCT00445276
Diacerein as Adjuvant to Diclofenac Sodium in Indian Patients of Osteoarthritis (OA) Knee
NCT01120015
Efficacy Management and Adherence Evaluation of Diclofenac in the Treatment of Knee Osteoarthritis Pain
NCT03806205
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is a previous study using osteoarthritis rat model as a biological basis of diacerein and celecoxib administration. Previous studies have shown that the combined use of Diacerein and Celecoxib improves osteoarthritis.
The purpose of this study is to evaluate the pain relief effect of Co-administration of Diacerein with Celecoxib in patients with knee osteoarthritis compared with single administration of each drug.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Co-administration group
Co-administration of Diacerein 50mg, Celecoxib 100mg.
Diacerein
For 12 weeks, administered twice a day by oral.
Celecoxib
For 12 weeks, administered twice a day by oral.
Single administration group 1
Single administration of Diacerein 50mg and placebo.
Diacerein
For 12 weeks, administered twice a day by oral.
Single administration group 2
Single administration of Celecoxib 100mg and placebo.
Celecoxib
For 12 weeks, administered twice a day by oral.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diacerein
For 12 weeks, administered twice a day by oral.
Celecoxib
For 12 weeks, administered twice a day by oral.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Adult over 50 years of age.
3. At least one of the knee pain VAS score is 40mm or more.
4. Meets the ACR(American College of Rheumatology) criteria for diagnosis. (1) Confirmation of osteophytes on radiographic inspection. (2) One or more of the following three items.
① Age\> 50 years
② Morning stiffness \<30 minutes
③ Crepitus
5. Patients who require medication for more than 12 weeks due to osteoarthritis symptoms.
6. Those who are able to follow the requirements of this clinical trial, such as being able to trace during the clinical trial period and to read and write the VAS questionnaire.
7. Those who weigh more than 40kg
Exclusion Criteria
2. Other inflammatory Knee Osteoarthritis (e.g. gout, rheumatoid arthritis, etc.)
3. Patients presenting with gastroesophageal reflux disease, peptic ulcer.
4. Helicobacter infected patients who have not been treated for eradication (recruitment if negative in re-examination after treatment).
5. Short bowel syndrome that can cause inflammatory bowel disease (ulcerative colitis, Crohn's disease) and drug absorption disorder.
6. Intestinal obstruction syndrome
7. Unexplained abdominal pain
8. ALT(Alanine aminotransferase) level of liver function test exceeded 5 times of reference range
9. Total bilirubin level exceeded 2 mg / dL
10. Serum albumin level less than 2 g / dL
11. Ascites
12. Hepatic encephalopathy
13. Hepatitis B, hepatitis C (excluding healthy carriers) or HIV positive
14. MDRD(Modification of Diet in Renal Disease) Estimated Glomerular filtration rate less than 60 mL / m2
15. Patients with hyperkalemia (over 5.5 meq / L)
16. history of asthma, acute rhinitis, nasal polyps, angioedema, urticaria or allergic reactions to aspirin or other non-steroidal anti-inflammatory drugs(including COX-2 inhibitors).
17. Malignant tumors other than basal cell or squamous cell carcinoma of the skin, CIN(Cervical Intraepitherial Neoplasia) and CIS(Carcinoma in situ) of the cervix, and intraepithelial carcinoma of other areas Within 5 years of consent date.
18. Medical history of hypersensitivity to the components of the investigational products. (The components of test drug 1 and 2, including the Rhein-based drug)
19. Patients with an allergic reaction to sulfonamide.
20. Patients with galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption.
21. Subjects who have not reached the prescribed period after receiving contraindicated medication or treatment before participation in this clinical trial.
22. Patients receiving contraindicated medication.
23. Alcohol and other drug abuse cases based on 6 months before screening.
24. Pregnant women or nursing mothers who are not willing to stop breastfeeding.
25. Female who do not fall into one or more of the following categories(In other words, only the following female can participate:)
* (1) Menopause (non-therapy-induced amenorrhea of more than 12 months) Female
* (2) Female infertility due to surgery (no ovaries and / or uterus)
* (3) If you have sexual intercourse with only one male partner who has been confirmed to have no semen after fertilization.
* (4) Female subjects who agreed to abstinence during the clinical trial period.
* If the subject is assured of an abstinence throughout the trial period.(e.g. clergy)
* However, intermittent abstinence (eg, contraception using ovulation period, symptothermal) or coitus interrupts is not a case of consent for abstinence.
* (5) For women of childbearing age, the following methods or methods of contraception use the effective method of contraception to be used during the period of this clinical trial:
* Oral contraceptive
* The contraceptive patch
* Intra uterine device (IUD)
* contraceptive implant
* contraceptive injection
* intrauterine hormonal apparatus
* Tubal ligation and infertility surgery
26. If 30 days have not elapsed after the date of signing of the previous clinical trial or currently participating in other clinical trials.
27. Patients who are scheduled for surgery during the clinical trial period or who have difficulties in completing the protocol during this clinical trial due to other reasons.
28. In addition to the above, other diseases that the investigator judges to be inappropriate.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Korea University Guro Hospital
OTHER
Whan-Seok Choi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Whan-Seok Choi
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Whan-Seok Choi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Seoul St. Mary's Hospital
Seon-Mee Kim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Korea University Guro Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul ST. Mary's Hospital
Seoul, , South Korea
Korea University Guro Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Li Z, Meng D, Li G, Xu J, Tian K, Li Y. Celecoxib Combined with Diacerein Effectively Alleviates Osteoarthritis in Rats via Regulating JNK and p38MAPK Signaling Pathways. Inflammation. 2015 Aug;38(4):1563-72. doi: 10.1007/s10753-015-0131-3.
Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104. doi: 10.1177/1759720X09359104.
Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015 Mar;38(3):245-52. doi: 10.1007/s40264-015-0266-z.
Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998 Nov;35(5):347-59. doi: 10.2165/00003088-199835050-00002.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DIA IIT_01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.